To report our clinical experience karyotyping trophectoderm biopsies using a targeted next-generation DNA sequencing (NGS) assay. Chromosome aneuploidy, often associated with increased maternal age, represents one of the most common reasons for the failure of assisted reproductive technologies (ART) such as in vitro fertilization (IVF) as the majority of aneuploid embryos either fail to implant or miscarry. Preimplantation genetic screening (PGS) offers a means to identify euploid embryos prior to implantation with the goal of increasing pregnancy and live birth rates. We have modified the FAST-SeqS method, which amplifies >10,000 repetitive LINE1 elements across the genome, in order to determine the molecular karyotype of trophectoderm biopsies from blastocyst-stage embryos. Good Start Genetics, Inc. (GSG) launched an NGS-based PGS assay, EmbryVu, in September 2015. Trophectoderm biopsies containing 5-10 cells from blastocyst-stage embryos from infertility patients scheduled for frozen embryo transfer were submitted for analysis. All samples, including biopsy wash-buffer negative controls, were analyzed using the EmbryVu assay and associated bioinformatics pipeline. We analyzed our EmbryVu data to date, including patient age, clinical indication, and NGS results. To date we have analyzed a total of 4625 embryos from 1007 patients. The age of female patients seeking PGS testing (including egg donors if used) ranged from 21 to 46. The largest age group, which made up approximately 21% of our dataset, was women ages 31-34. In the total population of biopsies, slightly less than half were aneuploid. As expected, the rate of aneuploidy varied between age groups, with a low of 31% in women ages 21-25 and a high of 89% in women ages 43-46. These results are highly concordant with published aneuploidy rates (Franasiak JM, et al. 2014). The majority of aneuploid embryos had a single abnormality; however, a small number of embryos had five or more abnormalities or were chaotic in nature. The most common abnormalities were trisomy 16, monosomy 22, monosomy 16 and monosomy 21. EmbryVu is a rapid, accurate, and cost-effective method for determining the euploid status of embryos scheduled for frozen transfer. The ability to determine embryos with the greatest chance of implantation and subsequent live birth is vital to improve IVF success rates. PGS has traditionally been reserved for patients with specific clinical indications (i.e. advanced maternal age) and has been cost-prohibitive to many. We believe advances in our accurate, lower cost NGS technology, coupled with mounting evidence that PGS increases positive outcomes, are making it possible for PGS to be offered to all IVF patients.